ImmuMap launches collaboration with Zelluna Immunotherapy

ImmuMap, a state-of-the-art flow cytometry services company, is entering into a collaboration with the innovative Norwegian company, Zelluna Immunotherapy, working on cutting-edge cellular immunotherapies based on T cell receptor technologies. We have already performed several studies together, including a large flow cytometry-based investigation of several of Zelluna’s T cell receptors. These studies will support the development of Zelluna’s portfolio and contribute to data packages leading to the anticipated first-in-human Zelluna study. ImmuMap has been created to deliver results around testing of projects such as TCRs with clinical potential. We look forward to having a rewarding relationship with Zelluna.”